References
1. Favier J, Amar L, Gimenez-Roqueplo AP. 2015. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 11 (2): 101-111.
2. Maher ER, Neumann HP, Richard S. 2011. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 19 (6): 617-623.
3. Lloyd R, Osamura R, Klöppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs, 4th edn IARC Press. Lyon: 2017.
4. Koh JM, Ahn SH, Kim H, et al. 2017. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One. 12 (11): e0187398.
5. Wachtel H, Hutchens T, Baraban E, et al. 2020. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems. J Clin Endocrinol Metab. 105 (12).
6. Pierre C, Agopiantz M, Brunaud L, et al. 2019. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. Virchows Arch. 474 (6): 721-734.
7. Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. 2014. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 81 (5): 642-651.
8. Pryma DA, Chin BB, Noto RB, et al. 2019. Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 60 (5): 623-630.
9. Satapathy S, Mittal BR, Bhansali A. 2019. ’Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis’. Clin Endocrinol (Oxf). 91 (6): 718-727.
10. Kohlenberg J, Welch B, Hamidi O, et al. 2019. Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma. Cancers (Basel). 11 (2).
11. Fassnacht M, Assie G, Baudin E, et al. 2020. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.31 (11): 1476-1490.
12. Ma X, Li M, Tong A, et al. 2020. Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study. Front Endocrinol (Lausanne). 11 : 574662.
Table 1. Endocrine function workup results in 2015 revealed no remarkable abnormality.